ArticleCommunications medicine2023
Increase in the community circulation of ciprofloxacin-resistant Escherichia coli despite reduction in antibiotic prescriptions.
Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Community-associated quinolone-resistant and extended-spectrum beta-lactamase-producingmSystems · 2026Article
- Fluoroquinolone Resistance Patterns in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- A Two-Year Retrospective Study of Blood Cultures in a Secondary Western Greece Healthcare Setting.Microorganisms · 2026Article
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Efficacy of adjuvant amikacin combined with oral levofloxacin as prophylaxis for transrectal prostate biopsy in patients harboring fluoroquinolone-resistant Escherichia coli in rectal flora.International urology and nephrology · 2025Article
- Infectious complications in patients undergoing transrectal prostate-biopsy with ciprofloxacin compared to fosfomycin-trometamol.World journal of urology · 2025Article
- Antibiotic Resistance and Molecular Epidemiology of ESBL-Producing E. coli in Shrimp Aquaculture: A Study from Tiruvallur District, Tamil Nadu, India.Current microbiology · 2025Article
- Rapid and accurate testing for urinary tract infection: new clothes for the emperor.Clinical microbiology reviews · 2025Review
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- Molecular Analysis ofMicroorganisms · 2024Article
- Gut residentmedRxiv : the preprint server for health sciences · 2024Article
- Sensitive Pathogen Detection and Drug Resistance Characterization Using Pathogen-Derived Enzyme Activity Amplified by LAMP or CRISPR-Cas.medRxiv : the preprint server for health sciences · 2024Article
- Antimicrobial resistance profiles ofJAC-antimicrobial resistance · 2024Article
- Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity ofFrontiers in cellular and infection microbiology · 2024Article
- Commensal Fitness Advantage May Contribute to the Global Dissemination of Multidrug-Resistant Lineages of Bacteria-The Case of UropathogenicPathogens (Basel, Switzerland) · 2023Article
Corrections and comments
- Update of
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCommunity circulating gut microbiota is the main reservoir for uropathogenic Escherichia coli, including those resistant to antibiotics. Ciprofloxacin had been the primary antibiotic prescribed for urinary tract infections, but its broad use has been discouraged and steadily declined since 2015. How this change in prescriptions affected the community circulation of ciprofloxacin-resistant E. coli is unknown.
methodsWe determined the frequency of isolation and other characteristics of E. coli resistant to ciprofloxacin in 515 and 1604 E. coli-positive fecal samples collected in 2015 and 2021, respectively. The samples were obtained from non-antibiotic-taking women of age 50+ receiving care in the Kaiser Permanente Washington healthcare system.
resultsHere we show that despite a nearly three-fold drop in the prescription of ciprofloxacin between 2015 and 2021, the rates of gut carriage of ciprofloxacin-resistant E. coli increased from 14.2 % to 19.8% (P = .004). This is driven by a significant increase of isolates from the pandemic multi-drug resistant clonal group ST1193 (1.7% to 4.2%; P = .009) and isolates with relatively few ciprofloxacin-resistance determining chromosomal mutations (2.3% to 7.4%; P = .00003). Though prevalence of isolates with the plasmid-associated ciprofloxacin resistance dropped (59.0% to 30.9%; P = 2.7E-06), the isolates co-resistance to third generation cephalosporins has increased from 14.1% to 31.5% (P = .002).
conclusionsDespite reduction in ciprofloxacin prescriptions, community circulation of the resistant uropathogenic E. coli increased with a rise of co-resistance to third generation cephalosporins. Thus, to reduce the rates of urinary tract infections refractory to antibiotic treatment, greater focus should be on controlling the resistant bacteria in gut microbiota.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.